A young patient at a neurologist’s appointment: features of diagnostics and therapy

Abstract

Outpatient neurological appointments in most cases consist of patients older than 45 years. The novel coronavirus pandemic has changed this statistic. Young patients began to turn to polyclinics more often with complaints of headache, feeling of weakness, decreased physical activity, forgetfulness, and changes in concentration. COVID-1 9 provoked the development of coagulopathy in patients with genetic mutations and signs of dysplasia. The percentage of patients with acquired or congenital thrombophilia has increased. Most of them had certain manifestations of undifferentiated dysplasia, with signs of impaired venous outflow with a characteristic cephalgic syndrome. The peculiarity of which is polymorphism, inconstancy, the absence, in most cases, of connection with specific vascular and hemodynamic factors (excluding headache in venous thrombosis), a decrease in the frequency of occurrence as the disease progresses. The presence of certain complaints (headache, asthenia, cognitive impairment) requires the appointment of specific therapy. Monotherapy with one drug, even if it has a pleiotropic effect, does not always achieve therapeutic goals, since one or another mechanism of pharmacological action prevails, and the rest are secondary, requiring enhancement or other drugs, or non-drug methods. Given the poor adherence of young patients to treatment, the way out of this situation is the use of combined drugs. Combination drugs can be used as multifunctional drugs, potentiating or summarizing their effects, while reducing the risk of polypharmacy and unwanted side reactions. One of the most promising combinations is Picamilon Ginkgo (Ginkgo biloba leaf extract + Nicotinoyl gamma-a minobutyric acid), which has established itself as an effective corrector of asthenia and cognitive impairment in patients of any age.